Follow our Journeys
Sharing success stories internal to Duke Capital Partners and external to our portfolio companies.
Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs
Tune Therapeutics, a Duke Capital Partners portfolio company, is a Duke spinout cofounded by Professor Charles Gersbach (BME, Pratt).
Durham-based Acre Homes Raises Over $10MM from VCs Amid Growing Consumer Demand for Single Family Housing Solutions
Acre Homes joins the Duke Capital Partners portfolio.
DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform to Characterize Drug Effects and Optimize Neurological Care
NOTE: DANNCE.ai, a start-up from the lab of Assistant Professor Timothy Dunn (BME, Pratt), is developing an automated way of tracking and quantifying movement to identify disease states and drug effects with support from the Gilhuly Accelerator Fund.…
Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B
Tune Therapeutics, a Duke Capital Partners portfolio company, is a Duke spinout cofounded by Professor Charles Gersbach (BME, Pratt).
Associate Spotlight: Faisal Anees
Faisal Anees shares how his combined BME, MEMS, and CS experience enhanced his work with DCP.
Sweaty Palms Move From Dorm Room to Board Room
Duke Today covers the acquisition of Carpe, a DCP portfolio company.
Read More about Sweaty Palms Move From Dorm Room to Board Room